JP2021512904A5 - - Google Patents
Info
- Publication number
- JP2021512904A5 JP2021512904A5 JP2020542613A JP2020542613A JP2021512904A5 JP 2021512904 A5 JP2021512904 A5 JP 2021512904A5 JP 2020542613 A JP2020542613 A JP 2020542613A JP 2020542613 A JP2020542613 A JP 2020542613A JP 2021512904 A5 JP2021512904 A5 JP 2021512904A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pharmaceutical composition
- composition according
- patient
- hydrogen
- Prior art date
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862627408P | 2018-02-07 | 2018-02-07 | |
| US62/627,408 | 2018-02-07 | ||
| US201862694318P | 2018-07-05 | 2018-07-05 | |
| US62/694,318 | 2018-07-05 | ||
| US201862772956P | 2018-11-29 | 2018-11-29 | |
| US62/772,956 | 2018-11-29 | ||
| PCT/US2019/016844 WO2019157050A1 (en) | 2018-02-07 | 2019-02-06 | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating anca associated vasculitides |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021512904A JP2021512904A (ja) | 2021-05-20 |
| JP2021512904A5 true JP2021512904A5 (https=) | 2022-02-16 |
| JPWO2019157050A5 JPWO2019157050A5 (https=) | 2022-02-16 |
Family
ID=67540670
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020542613A Pending JP2021512904A (ja) | 2018-02-07 | 2019-02-06 | Ａｎｃａ関連血管炎の治療のためのある種の（２ｓ）−ｎ−［（１ｓ）−１−シアノ−２−フェニル］−１，４−オキサゼパン−２−カルボキサミド |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US20200390781A1 (https=) |
| EP (1) | EP3749326A4 (https=) |
| JP (1) | JP2021512904A (https=) |
| KR (1) | KR20200118103A (https=) |
| AU (1) | AU2019217870A1 (https=) |
| CA (1) | CA3089240A1 (https=) |
| WO (1) | WO2019157050A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2699580T3 (https=) | 2014-01-24 | 2018-02-24 | ||
| KR20250002710A (ko) | 2018-03-01 | 2025-01-07 | 아스트라제네카 에이비이 | (2s)-n-｛(1s)-1-시아노-2-[4-(3-메틸-2-옥소-2,3-디하이드로-1,3-벤족사졸-5-일)페닐]에틸｝-1,4-옥사제판-2-카복스아미드를포함하는 약학 조성물 |
| US20210252015A1 (en) * | 2018-07-17 | 2021-08-19 | Insmed Incorporated | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating inflammatory bowel disease |
| AU2019306532A1 (en) | 2018-07-17 | 2021-03-04 | Insmed Incorporated | Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating Lupus Nephritis |
| CN116157687A (zh) * | 2020-07-20 | 2023-05-23 | 英斯梅德股份有限公司 | 用于提取嗜中性粒细胞丝氨酸蛋白酶以及治疗二肽基肽酶1介导的病症的方法 |
| CN115996923B (zh) | 2020-08-26 | 2025-07-18 | 海思科医药集团股份有限公司 | 一种作为二肽基肽酶1抑制剂的腈衍生物及其用途 |
| US20240150335A1 (en) * | 2021-02-05 | 2024-05-09 | Medshine Discovery Inc. | Fused ring derivatives containing 1,4-oxazepane |
| EP4450497A4 (en) * | 2022-01-11 | 2025-11-26 | Shanghai Yidian Pharmaceutical Tech Development Co Ltd | NITRILE PEPTIDYL COMPOUND AND ITS USES |
| EP4479059A4 (en) * | 2022-02-16 | 2026-01-28 | Insmed Inc | CERTAIN N-(1-CYANO-2-PHENYLETHYL)-1,4-OXAZEPANE-2-CARBOXAMIDES FOR THE TREATMENT OF HIDRADENITIS SUPPURATIVE |
| TW202413352A (zh) | 2022-06-13 | 2024-04-01 | 日商模數探索股份有限公司 | 氮雜環烷基羰基環狀胺化合物 |
| EP4646265A1 (en) | 2023-01-06 | 2025-11-12 | Insmed Incorporated | Novel, reversible dpp1 inhibitors and uses thereof |
| JP2026507449A (ja) * | 2023-02-15 | 2026-03-04 | インスメッド インコーポレイテッド | Ｄｐｐ１阻害剤としてのある特定の１，４－オキサゼパン－２－カルボキサミドの使用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2580271A1 (en) * | 2004-10-05 | 2006-04-20 | Genentech, Inc. | Method for treating vasculitis |
| CA2863723C (en) * | 2012-02-21 | 2020-09-22 | Carl Deutsch | 8-substituted 2-amino-[1,2,4]triazolo[1,5-a]pyrazines as syk tryrosine kinase inhibitors and gcn2 serin kinase inhibitors |
| WO2014091443A1 (en) * | 2012-12-13 | 2014-06-19 | Glaxo Group Limited | Cathepsin c inhibitors for treating cystic fibrosis, non-cystic fibrosis bronchiectasis, and anca-associated vasculitis |
| JP6437929B2 (ja) * | 2013-03-14 | 2018-12-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | カテプシンｃの置換二環式１−カルボン酸（ベンジル−シアノ−メチル）−アミド阻害剤 |
| NO2699580T3 (https=) * | 2014-01-24 | 2018-02-24 | ||
| JP6529575B2 (ja) * | 2014-08-01 | 2019-06-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 置換オキセタンおよびそれらのカテプシンｃの阻害薬としての使用 |
| KR102510588B1 (ko) * | 2014-09-12 | 2023-03-17 | 베링거 인겔하임 인터내셔날 게엠베하 | 카텝신 c의 스피로사이클릭 억제제 |
| KR20250107292A (ko) * | 2016-07-29 | 2025-07-11 | 인스메드 인코포레이티드 | 기관지확장증을 치료하기 위한 특정 (2s)-n-[(1s)-1-시아노-2-페닐에틸]-1,4-옥사제판-2-카르복스아미드 |
-
2019
- 2019-02-06 AU AU2019217870A patent/AU2019217870A1/en not_active Abandoned
- 2019-02-06 WO PCT/US2019/016844 patent/WO2019157050A1/en not_active Ceased
- 2019-02-06 US US16/968,381 patent/US20200390781A1/en not_active Abandoned
- 2019-02-06 JP JP2020542613A patent/JP2021512904A/ja active Pending
- 2019-02-06 CA CA3089240A patent/CA3089240A1/en active Pending
- 2019-02-06 KR KR1020207025220A patent/KR20200118103A/ko not_active Withdrawn
- 2019-02-06 EP EP19751012.6A patent/EP3749326A4/en not_active Withdrawn
- 2019-02-06 US US16/269,191 patent/US20190247400A1/en not_active Abandoned
-
2021
- 2021-01-25 US US17/157,216 patent/US20210186984A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021512904A5 (https=) | ||
| JP2022096662A5 (https=) | ||
| JP2023156479A5 (https=) | ||
| JP2021530513A5 (https=) | ||
| JP5749802B2 (ja) | 非定型抗精神病薬及びｔａａｒ１アゴニストを含む組合せ | |
| JP2021530525A5 (https=) | ||
| JP2021515006A5 (https=) | ||
| TW202327569A (zh) | 包含ｔｅａｄ抑制劑的藥物組合及其用於癌症治療之用途 | |
| CN1155409C (zh) | 用于预防和治疗动脉硬化的药物组合物 | |
| JP2022191257A5 (https=) | ||
| RU2000114635A (ru) | Бензотиазольные ингибиторы протеинтирозинкиназ | |
| CN1311675A (zh) | 具有lgE影响性能的化合物 | |
| JPWO2019157050A5 (https=) | ||
| WO2002005797A2 (en) | Use of dopamine d2/d3 receptor agonists to treat fibromyalgia | |
| SK112001A3 (en) | Agents with an antidepressive effect containing pramipexol and an additional antidepressant drug | |
| EP3749326A1 (en) | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating anca associated vasculitides | |
| RU2010117178A (ru) | Опосредованная самокомплементарными aav доставка молекул, интерферирующих рнк для лечения или профилактики глазных заболеваний | |
| WO2019046287A1 (en) | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HEPATITIS B | |
| WO2020018547A1 (en) | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis | |
| WO2019151470A1 (ja) | 眼内血管新生及び／又は眼内血管透過性亢進を伴う眼科疾患の予防又は治療のための医薬 | |
| JPWO2020018551A5 (https=) | ||
| JPWO2019166626A5 (https=) | ||
| JPWO2021048822A5 (https=) | ||
| CN1233178A (zh) | 用于治疗性功能障碍的吡唑啉酮类 | |
| US20020147206A1 (en) | Combination treatment of multiple sclerosis (MS), other demyelinating conditions and peripheral neuropathy, especially painful neuropathies and diabetic neuropathy |